ISSN 1725-2423

Official Journal of the European Union

C 209

Volume 48

English edition

26 August 2005

Information and Notices

Notice No | Contents | Page

I *Information*

Commission

2005/C 209/01 Euro exchange rates 1

2005/C 209/02 Notice of the impending expiry of certain anti-dumping measures 2

2005/C 209/03 Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 July 2005 to 31 July 2005 *(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)* 3

EN

I

(Information)

COMMISSION

Euro exchange rates [1]

25 August 2005

(2005/C 209/01)

1 euro =

	Currency	Exchange rate		Currency	Exchange rate
USD	US dollar	1,2272	SIT	Slovenian tolar	239,50
JPY	Japanese yen	135,02	SKK	Slovak koruna	38,865
DKK	Danish krone	7,4573	TRY	Turkish lira	1,6760
GBP	Pound sterling	0,68200	AUD	Australian dollar	1,6173
SEK	Swedish krona	9,3313	CAD	Canadian dollar	1,4621
CHF	Swiss franc	1,5478	HKD	Hong Kong dollar	9,5376
ISK	Iceland króna	77,89	NZD	New Zealand dollar	1,7575
NOK	Norwegian krone	7,9255	SGD	Singapore dollar	2,0521
BGN	Bulgarian lev	1,9557	KRW	South Korean won	1 256,90
CYP	Cyprus pound	0,5729	ZAR	South African rand	7,9609
CZK	Czech koruna	29,698	CNY	Chinese yuan renminbi	9,9406
EEK	Estonian kroon	15,6466	HRK	Croatian kuna	7,3865
HUF	Hungarian forint	245,60	IDR	Indonesian rupiah	12 670,84
LTL	Lithuanian litas	3,4528	MYR	Malaysian ringgit	4,625
LVL	Latvian lats	0,6961	PHP	Philippine peso	68,785
MTL	Maltese lira	0,4293	RUB	Russian rouble	34,9710
PLN	Polish zloty	4,0430	THB	Thai baht	50,409
RON	Romanian leu	3,5144			

[1] *Source:* reference exchange rate published by the ECB.

Notice of the impending expiry of certain anti-dumping measures

(2005/C 209/02)

1. As provided for in Article 11(2) of Council Regulation (EC) No 384/96 of 22 December 1995 [1] on protection against dumped imports from countries not members of the European Community, the Commission gives notice that, unless a review is initiated in accordance with the following procedure, the anti-dumping measures mentioned below will expire on the date mentioned in the table below.

2. **Procedure**

Community producers may lodge a written request for a review. This request must contain sufficient evidence that the expiry of the measures would be likely to result in a continuation or recurrence of dumping and injury.

Should the Commission decide to review the measures concerned, importers, exporters, representatives of the exporting country and Community producers will then be provided with the opportunity to amplify, rebut or comment on the matters set out in the review request.

3. **Time limit**

Community producers may submit a written request for a review on the above basis, to reach the European Commission, Directorate-General for Trade (Division B-1), J-79 5/16, B-1049 Brussels [2] at any time from the date of the publication of the present notice but no later than three months before the date mentioned in the table below.

4. This notice is published in accordance with Article 11(2) of Council Regulation (EC) No 384/96 of 22 December 1995.

Product	Country(ies) of origin or exportation	Measures	Reference	Date of expiry
Urea	Russia	Anti-dumping duty	Council Regulation (EC) No 901/2001 (OJ L 127, 9.5.2001, p. 11)	10.5.2006
Aluminium foil	People's Republic of China Russia	Anti-dumping duty	Council Regulation (EC) No 950/2001 (OJ L 134, 17.5.2001, p. 1) as last amended by Regulation (EC) No 998/2004 (OJ L 183, 20.5.2004, p. 4)	18.5.2006
	Russia	Undertaking	Commission Decision No 2001/381/EC (OJ L 134, 17.5.2001, p. 67)	18.5.2006

[1] OJ L 56, 6.3.1996, p. 1. Regulation as last amended by Council Regulation (EC) No 461/2004 (OJ L 77, 13.3.2004, p. 12).

[2] Telefax : (32-2) 295 65 05.

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 July 2005 to 31 July 2005

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 ([1]))

(2005/C 209/03)

— Modification of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
4.7.2005	Apidra	Aventis Pharma Deutschland GmbH, Brueningstrasse 50, D-65926 Frankfurt am Main	EU/1/04/285/001-028	6.7.2005
4.7.2005	Forcaltonin	Unigene UK Limited, 63 High Road, Bushey Heath, Herts, WD2 1EE, United Kingdom	EU/1/98/093/002	6.7.2005
4.7.2005	Trisenox	Cell Therapeutics (UK) Ltd, 100 Pall Mall, London SW1Y 5HP, United Kingdom	EU/1/02/204/001	6.7.2005
4.7.2005	Levemir	Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd	EU/1/04/278/001-009	6.7.2005
4.7.2005	Zerene	Wyeth Research (UK) Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom	EU/1/99/099/001-006	6.7.2005
4.7.2005	Sonata	Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom	EU/1/99/102/001-008	6.7.2005
4.7.2005	Cymbalta	Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland	EU/1/04/296/001-006	6.7.2005
4.7.2005	Cymbalta	Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland	EU/1/04/296/001-006	6.7.2005
4.7.2005	Xeristar	Boehringer Ingelheim International GmbH, Binger Strasse 173 — D-55216 Ingelheim am Rhein	EU/1/04/297/001-006	6.7.2005
4.7.2005	Xeristar	Boehringer Ingelheim International GmbH, Binger Strasse 173 — D-55216 Ingelheim am Rhein	EU/1/04/297/001-006	6.7.2005
4.7.2005	Visudyne	Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/00/140/001	6.7.2005
4.7.2005	Xigris	Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland	EU/1/02/225/001-002	6.7.2005
7.7.2005	Invanz	Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/02/216/001-002	11.7.2005
7.7.2005	Arixtra	Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom	EU/1/02/206/001-008	11.7.2005

([1]) OJ L 214 of 24.8.1993, p. 1.

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
7.7.2005	Quixidar	Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom	EU/1/02/207/001-008	11.7.2005
7.7.2005	Cystagon	Orphan Europe, Immeuble 'Le Guillaumet', F-92046 Paris La Défense	EU/1/97/039/001-004	11.7.2005
8.7.2005	Glivec	Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/01/198/001-013	12.7.2005
8.7.2005	Aranesp	Amgen Europe BV, Minervum 7061, 4817 ZK Breda, Nederland	EU/1/01/185/001-056	12.7.2005
8.7.2005	Nespo	Dompé Biotec SpA, Via San Martino, 12, I-20122 Milano	EU/1/01/184/001-056	12.7.2005
8.7.2005	Lyrica	PFIZER Ltd, Ramsgate Road, Sandwich, Kent CT 13 9NJ, United Kingdom	EU/1/04/279/030-032	12.7.2005
8.7.2005	Fortovase	Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom	EU/1/98/075/001-002	12.7.2005
8.7.2005	AVANDIA	SmithKline Beecham plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom	EU/1/00/137/001-012	12.7.2005
8.7.2005	NovoRapid	Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd	EU/1/99/119/003 EU/1/99/119/005-007 EU/1/99/119/009-014	12.7.2005
8.7.2005	NeuroBloc	Elan Pharma International Ltd., WIL House, Shannon Business Park, Shannon, County Clare, Ireland	EU/1/00/166/001-003	13.7.2005
8.7.2005	Simulect	Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/98/084/001-002	12.7.2005
8.7.2005	Zevalin	Schering AG, Müllerstrasse 170-178, D-13342 Berlin	EU/1/03/264/001	12.7.2005
8.7.2005	Viread	Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom	EU/1/01/200/001	12.7.2005
8.7.2005	Keppra	UCB SA, Allée de la recherche, 60, B-1070 Bruxelles/Researchdreef, 60, B-1070 Brussel	EU/1/00/146/001-027	12.7.2005
8.7.2005	Lantus	Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main	EU/1/00/134/001-029	12.7.2005
8.7.2005	Optisulin	Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main	EU/1/00/133/001-008	12.7.2005
13.7.2005	NeoRecormon	Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom	EU/1/97/031/001-003 EU/1/97/031/019-046	15.7.2005

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
22.7.2005	Enbrel	Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom	EU/1/99/126/001-011	26.7.2005
22.7.2005	KOGENATE Bayer	Bayer AG, D-51368 Leverkusen	EU/1/00/143/001-006	26.7.2005
27.7.2005	Vaniqa	Shire Pharmaceutical Contracts Ltd, Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP, United Kingdom	EU/1/01/173/001-003	29.7.2005
27.7.2005	Infergen	Yamanouchi Europe B.V., Elisabethhof 19, 2353 EW Leiderdorp, Nederland	EU/1/98/087/001-003	29.7.2005
27.7.2005	Zevalin	Schering AG, Müllerstrasse 170-178, D-13342 Berlin	EU/1/03/264/001	29.7.2005
27.7.2005	Replagal	TKT Europe AB, Rinkebyvägen 11B, S-182 36 Danderyd	EU/1/01/189/001-006	29.7.2005
27.7.2005	Velcade	Janssen-Cilag International NV, Turnhoutseweg, 30 B-2340 Beerse	EU/1/04/274/001	29.7.2005
27.7.2005	AVANDIA	SmithKline Beecham plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom	EU/1/00/137/001-012	29.7.2005
27.7.2005	ReFacto	Wyeth Europa Ltd., Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom	EU/1/99/103/001-004	29.7.2005
28.7.2005	Kineret	Amgen Europe BV, Minervum 7061, 4817 ZK Breda, Nederland	EU/1/02/203/001-004	1.8.2005

— **Issuing of a marketing authorization (Article 34 of Council Regulation (EEC) No 2309/93): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
8.7.2005	Equilis Prequenza	Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland	EU/2/05/056/001-002	12.7.2005
8.7.2005	Equilis Prequenza Te	Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland	EU/2/05/057/001-002	12.7.2005
8.7.2005	Equilis Te	Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland	EU/2/05/055/001-002	12.7.2005
27.7.2005	Profender	Bayer Healthcare AG, D-51368 Leverkusen	EU/2/05/054/001-017	29.7.2005

— **Modification of a marketing authorization (Article 34 of Council Regulation (EEC) No 2309/93): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
7.7.2005	Neocolipor	Merial, 29 avenue Tony Garnier, F-69007 Lyon	EU/2/98/008/001-004	11.7.2005
8.7.2005	Ibaflin	Intervet International BV, Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland	EU/2/00/022/001a-001b, 002a-002b, 003a-003b, 004a-004b, EU/2/00/022/005-017,	12.7.2005

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
7, Westferry Circus, Canary Wharf
London E14 4HB
United Kingdom